Adam B Weiner, Raag Agrawal, Luca F Valle, Ida Sonni, Amar U Kishan, Matthew B Rettig, Steven S Raman, Jeremie Calais, Paul C Boutros, Robert E Reiter
{"title":"PSMA PET 对前列腺癌管理的影响。","authors":"Adam B Weiner, Raag Agrawal, Luca F Valle, Ida Sonni, Amar U Kishan, Matthew B Rettig, Steven S Raman, Jeremie Calais, Paul C Boutros, Robert E Reiter","doi":"10.1007/s11864-024-01181-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Opinion statement: </strong>PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.</p>","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":" ","pages":"191-205"},"PeriodicalIF":3.8000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034977/pdf/","citationCount":"0","resultStr":"{\"title\":\"Impact of PSMA PET on Prostate Cancer Management.\",\"authors\":\"Adam B Weiner, Raag Agrawal, Luca F Valle, Ida Sonni, Amar U Kishan, Matthew B Rettig, Steven S Raman, Jeremie Calais, Paul C Boutros, Robert E Reiter\",\"doi\":\"10.1007/s11864-024-01181-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Opinion statement: </strong>PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.</p>\",\"PeriodicalId\":50600,\"journal\":{\"name\":\"Current Treatment Options in Oncology\",\"volume\":\" \",\"pages\":\"191-205\"},\"PeriodicalIF\":3.8000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11034977/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Treatment Options in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11864-024-01181-9\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/25 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Treatment Options in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11864-024-01181-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
意见陈述：PSMA-PET已成为改变男性PCa患者治疗实践的成像生物标志物。研究表明，在许多情况下，PSMA-PET 比传统成像和其他 PET 放射性标记物更准确。随着多种 PSMA 靶向放射性同位素获得批准，PSMA PET 将更多地应用于临床实践。要更多地使用PSMA PET，就必须了解现有的前瞻性数据，并谨慎推断使用其他成像模式的先前试验数据。未来利用 PSMA PET 进行治疗优化和管理决策的试验将最终推动其临床应用。
Opinion statement: PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.
期刊介绍：
This journal aims to review the most important, recently published treatment option advances in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to facilitate worldwide approaches to cancer treatment.
We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as endocrine tumors, lymphomas, neuro-oncology, and cancers of the breast, head and neck, lung, skin, gastrointestinal tract, and genitourinary region. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. We also provide commentaries from well-known oncologists, and an international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
